ClinicalTrials.gg

Program

YMI024

A development code.

Its studies are mostly in Coronary Artery Disease, led by Novartis.

Furthest: phase 2, since Sep 15, 20261 company-led study, 1 open or runningNext primary completion: Aug 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Sep 15, 2026Sep 15, 2026Aug 15, 2027phase 2 · NCT07830719
  • Named in Novartis’s own pipeline as YMI024, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2026First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT07830719 · 180 planned · United States, Australia, Germany and more

Ahead

  1. Aug 15, 2027Primary completion: phase 2 study in Coronary Artery DiseaseNCT07830719

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07830719Coronary Artery Disease · United States, Australia, Germany and more2RecruitingAug 15, 2027180

How it is read

Names in the registry

  • “YMI024”, 1 entry

Codes read as this program: YMI024.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.